(NSCLC) East Asian Subgroup Analysis: Docetaxel Plus Ramucirumab (Cyramza) — REVEL Phase 3 Trial

• March 22, 2016
• 1 min read

On February 22, 2016, Cancer Research and Treatment published a Phase 3 clinical trial subgroup analysis for non-small cell lung cancer (NSCLC) patients. This trial evaluated platinum-based chemotherapy combinations including docetaxel (taxotere), ramucirumab (Cyramza), and placebo. The original results were published in The Lancet in February 2014. This report presents the subgroup analysis for Asian patients.

The East Asian subgroup analysis (Taiwan and South Korea) enrolled 82 patients with Stage IV NSCLC. Docetaxel plus ramucirumab was evaluated for overall survival, adverse events, and response rate. Results showed a median overall survival of 10.3 months with combination therapy. Reducing the docetaxel dose to 60 mg/m² was associated with a lower frequency of adverse events. Based on these results, this treatment regimen was adopted in Japan the following year.

Detailed clinical trial data showing differences by dosage are available via the link below.

Source: East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy (REVEL). Cancer Res Treat. 2016 Feb 22. doi:10.4143/crt.2015.401.

Lung Cancer | Ramucirumab | Docetaxel | REVEL

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4